| Literature DB >> 28842466 |
Aaron R Victor1, Ansel P Nalin1, Wenjuan Dong2, Susan McClory1,2, Min Wei2, Charlene Mao2, Raleigh D Kladney2,3,4, Youssef Youssef5, Wing Keung Chan2, Edward L Briercheck1,2, Tiffany Hughes2, Steven D Scoville1,2, Jason R Pitarresi2,3, Charlie Chen2, Sarah Manz2, Lai-Chu Wu2, Jianying Zhang6, Michael C Ostrowski2,3, Aharon G Freud2,5, Gustavo W Leone2,3,4, Michael A Caligiuri7,8, Jianhua Yu7,8.
Abstract
Group 3 innate lymphoid cells (ILC3s) are important regulators of the immune system, maintaining homeostasis in the presence of commensal bacteria, but activating immune defenses in response to microbial pathogens. ILC3s are a robust source of IL-22, a cytokine critical for stimulating the antimicrobial response. We sought to identify cytokines that can promote proliferation and induce or maintain IL-22 production by ILC3s and determine a molecular mechanism for this process. We identified IL-18 as a cytokine that cooperates with an ILC3 survival factor, IL-15, to induce proliferation of human ILC3s, as well as induce and maintain IL-22 production. To determine a mechanism of action, we examined the NF-κB pathway, which is activated by IL-18 signaling. We found that the NF-κB complex signaling component, p65, binds to the proximal region of the IL22 promoter and promotes transcriptional activity. Finally, we observed that CD11c+ dendritic cells expressing IL-18 are found in close proximity to ILC3s in human tonsils in situ. Therefore, we identify a new mechanism by which human ILC3s proliferate and produce IL-22, and identify NF-κB as a potential therapeutic target to be considered in pathologic states characterized by overproduction of IL-18 and/or IL-22.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28842466 PMCID: PMC5624342 DOI: 10.4049/jimmunol.1601554
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.422